JP2017510585A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510585A5
JP2017510585A5 JP2016558751A JP2016558751A JP2017510585A5 JP 2017510585 A5 JP2017510585 A5 JP 2017510585A5 JP 2016558751 A JP2016558751 A JP 2016558751A JP 2016558751 A JP2016558751 A JP 2016558751A JP 2017510585 A5 JP2017510585 A5 JP 2017510585A5
Authority
JP
Japan
Prior art keywords
formulation
item
lyophilized
less
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016558751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510585A (ja
JP7058940B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022141 external-priority patent/WO2015148444A1/en
Publication of JP2017510585A publication Critical patent/JP2017510585A/ja
Publication of JP2017510585A5 publication Critical patent/JP2017510585A5/ja
Priority to JP2022007013A priority Critical patent/JP7503583B2/ja
Application granted granted Critical
Publication of JP7058940B2 publication Critical patent/JP7058940B2/ja
Priority to JP2024033771A priority patent/JP7759978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016558751A 2014-03-24 2015-03-24 凍結乾燥第ix因子製剤 Active JP7058940B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007013A JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ix因子製剤
JP2024033771A JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ix因子製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24
US61/969,801 2014-03-24
PCT/US2015/022141 WO2015148444A1 (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020016131A Division JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ix因子製剤
JP2022007013A Division JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ix因子製剤

Publications (3)

Publication Number Publication Date
JP2017510585A JP2017510585A (ja) 2017-04-13
JP2017510585A5 true JP2017510585A5 (enExample) 2018-05-10
JP7058940B2 JP7058940B2 (ja) 2022-04-25

Family

ID=54196282

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016558751A Active JP7058940B2 (ja) 2014-03-24 2015-03-24 凍結乾燥第ix因子製剤
JP2020016131A Pending JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ix因子製剤
JP2022007013A Active JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ix因子製剤
JP2024033771A Active JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ix因子製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020016131A Pending JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ix因子製剤
JP2022007013A Active JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ix因子製剤
JP2024033771A Active JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ix因子製剤

Country Status (16)

Country Link
US (3) US10772942B2 (enExample)
EP (1) EP3123090A4 (enExample)
JP (4) JP7058940B2 (enExample)
KR (1) KR102385372B1 (enExample)
AR (1) AR099838A1 (enExample)
AU (2) AU2015236340B2 (enExample)
CA (1) CA2943034C (enExample)
CL (1) CL2016002386A1 (enExample)
EA (2) EA202092926A3 (enExample)
IL (3) IL247869B (enExample)
MA (1) MA39779A (enExample)
MX (2) MX387269B (enExample)
PH (1) PH12016501877A1 (enExample)
SG (3) SG10201913735SA (enExample)
TW (1) TWI700101B (enExample)
WO (1) WO2015148444A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788044B (zh) * 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ix多肽調配物
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
BR112019011115A2 (pt) * 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc. métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
MX2020000480A (es) * 2017-07-11 2020-09-10 Universal Stabilization Tech Inc Método para la conservación de material biológico.
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
MX2022009558A (es) 2020-02-04 2022-09-09 Regeneron Pharma Contenido de humedad residual objetivo para farmaco liofilizado.
JP2023526024A (ja) * 2020-05-11 2023-06-20 アルカームス ファーマ アイルランド リミテッド Il-2融合ポリペプチド組成物ならびにその作製及び使用方法
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
WO1990009800A1 (en) 1989-02-21 1990-09-07 Washington University Modified forms of reproductive hormones
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
KR20020063853A (ko) * 1999-09-17 2002-08-05 다케다 야쿠힌 고교 가부시키가이샤 단백질 분체의 제조 방법
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
EP1427820A2 (en) 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified factor ix
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
CA2554018A1 (en) 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
LT2371856T (lt) 2004-11-12 2022-08-25 Bayer Healthcare Llc Fviii modifikacija, nukreipta į tam tikrą vietą
KR101283736B1 (ko) 2004-12-15 2013-07-08 스위디쉬 오르펀 바이오비트럼 에이비(피유비엘) 케라티노사이트 성장 인자의 치료학적 제형
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
BRPI0618133A2 (pt) 2005-11-01 2011-08-16 Wyeth Corp solução de cloreto de sódio para reconstituição ou diluição de droga
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2004683B1 (en) 2006-03-24 2016-05-11 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
KR101504969B1 (ko) 2006-04-04 2015-03-24 샤이어 파마슈티칼스 아일랜드 리미티드 폴리펩타이드의 농축 방법
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
KR101631323B1 (ko) 2007-06-21 2016-06-17 엑스엘-프로테인 게엠베하 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
CN101903030A (zh) 2007-12-21 2010-12-01 灵感生物制药学有限公司 含海藻糖的稳定化因子ix制剂
NZ585835A (en) 2007-12-27 2012-07-27 Baxter Int Chemically modified factor IX comprising a hydrophilic polymer attached via a releasable linker
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ix因子の部位特異的修飾
WO2009137254A2 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
WO2009130198A2 (en) 2008-04-21 2009-10-29 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
AU2009239641B2 (en) 2008-04-24 2013-11-07 Cantab Biopharmaceuticals Patents Limited Factor IX conjugates with extended half-lives
ES2755029T3 (es) 2008-08-05 2020-04-21 Wyeth Llc Liofilización por encima de la temperatura de colapso
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法
US20120114646A1 (en) 2009-06-18 2012-05-10 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
EA028067B1 (ru) 2010-07-09 2017-10-31 Байоджен Хемофилия Инк. Способы контроля или предотвращения кровотечения или эпизодов кровотечения
US20130217708A1 (en) 2010-09-30 2013-08-22 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
WO2014052490A1 (en) * 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ix多肽調配物
SG10201913735SA (en) * 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations

Similar Documents

Publication Publication Date Title
JP2017510585A5 (enExample)
EP2373293B2 (en) Compositions with reduced dimer formation
US7879805B2 (en) High temperature stable peptide formulation
EP1308170B1 (en) Dried blood factor composition comprising trehalose
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP2005526084A5 (enExample)
CN104159614A (zh) TNF-α抗体的药物制剂
JP2012121894A (ja) Il−1アンタゴニスト製剤
CN102869373A (zh) 不含白蛋白的肉毒杆菌毒素制剂
TW201424748A (zh) 高濃度抗體及蛋白質調配物
JP2016516722A5 (enExample)
JP2010531340A (ja) 新規処方物
CN106687126B (zh) 因子viii制剂
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
TW201605468A (zh) 長效人類生長激素接合物之製劑
ES2365832T3 (es) Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
CA2683317A1 (en) Stabilization of liquid solutions of recombinant protein for frozen storage
JP6166470B2 (ja) ゴナドトロピンのための新規製剤
JP4564652B2 (ja) 0.5ml未満の容量を投与するための凍結乾燥タンパク質組成物を含む1回量注射器
KR20110015552A (ko) 건조한 트랜스글루타미나제 조성물
AU2021227095B2 (en) Daptomycin formulation
JP2022514942A (ja) ペグアスパラガーゼの凍結乾燥組成物
CN108348458A (zh) Fviii制剂
JPWO2016080367A1 (ja) 安定化されたペプチド組成物
KR20230146515A (ko) 개선된 동결건조 제형